Intrinsic Differences in Spatiotemporal Organization and Stromal Cell Interactions Between Isogenic Lung Cancer Cells of Epithelial and Mesenchymal Phenotypes Revealed by High-Dimensional Single-Cell Analysis of Heterotypic 3D Spheroid Models.
drug resistance
erlotinib-resistance
heterotypic 3D models
imaging mass cytometry
in vitro cell culture models
non-small cell lung cancer (NSCLC)
tumor microenvironment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
11
2021
accepted:
22
03
2022
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
The lack of inadequate preclinical models remains a limitation for cancer drug development and is a primary contributor to anti-cancer drug failures in clinical trials. Heterotypic multicellular spheroids are three-dimensional (3D) spherical structures generated by self-assembly from aggregates of two or more cell types. Compared to traditional monolayer cell culture models, the organization of cells into a 3D tissue-like structure favors relevant physiological conditions with chemical and physical gradients as well as cell-cell and cell-extracellular matrix (ECM) interactions that recapitulate many of the hallmarks of cancer
Identifiants
pubmed: 35530312
doi: 10.3389/fonc.2022.818437
pmc: PMC9076321
doi:
Types de publication
Journal Article
Langues
eng
Pagination
818437Informations de copyright
Copyright © 2022 Lotsberg, Røsland, Rayford, Dyrstad, Ekanger, Lu, Frantz, Stuhr, Ditzel, Thiery, Akslen, Lorens and Engelsen.
Déclaration de conflit d'intérêts
Author AR was employed by BerGenBio. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancers (Basel). 2021 Oct 13;13(20):
pubmed: 34680267
Mol Syst Biol. 2020 Dec;16(12):e9798
pubmed: 33369114
Cancer Res. 2011 Nov 1;71(21):6857-66
pubmed: 21908556
Semin Radiat Oncol. 2015 Apr;25(2):87-92
pubmed: 25771412
Dev Cell. 2010 Jun 15;18(6):884-901
pubmed: 20627072
Front Oncol. 2017 Dec 11;7:293
pubmed: 29322028
Nat Rev Cancer. 2006 Aug;6(8):583-92
pubmed: 16862189
Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2893-7
pubmed: 1707175
J Cell Physiol. 2019 Jun;234(6):8352-8380
pubmed: 30443904
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Int J Radiat Biol Relat Stud Phys Chem Med. 1970;18(5):491-5
pubmed: 5316564
Cancer Immunol Res. 2019 Nov;7(11):1789-1802
pubmed: 31488404
SLAS Discov. 2017 Jun;22(5):456-472
pubmed: 28520521
NPJ Precis Oncol. 2021 Jul 15;5(1):65
pubmed: 34267282
Front Med. 2018 Aug;12(4):361-373
pubmed: 30043221
Cancers (Basel). 2021 Feb 24;13(5):
pubmed: 33668151
PLoS One. 2011;6(7):e23062
pubmed: 21829586
FASEB J. 2008 Sep;22(9):3120-8
pubmed: 18495755
Anal Biochem. 2013 Feb 15;433(2):105-11
pubmed: 23085117
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Science. 2013 Nov 8;342(6159):1234850
pubmed: 24202173
Proc Natl Acad Sci U S A. 1989 Sep;86(18):7043-7
pubmed: 2780560
Trends Cell Biol. 2011 Dec;21(12):745-54
pubmed: 22033488
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Curr Opin Genet Dev. 2003 Aug;13(4):365-71
pubmed: 12888009
Cancer Res. 2010 Sep 1;70(17):6945-56
pubmed: 20699369
PLoS One. 2014 Mar 17;9(3):e92248
pubmed: 24638075
Int J Dev Biol. 2004;48(5-6):397-409
pubmed: 15349815
J Thorac Oncol. 2020 Jun;15(6):973-999
pubmed: 32018052
Cell Cycle. 2011 Sep 1;10(17):2865-73
pubmed: 21862874
Curr Opin Genet Dev. 2005 Feb;15(1):97-101
pubmed: 15661539
Basic Clin Pharmacol Toxicol. 2015 Jan;116(1):9-18
pubmed: 25154903
Sci Rep. 2016 Jan 11;6:19103
pubmed: 26752500
Oncotarget. 2016 Aug 9;7(32):52575-52583
pubmed: 27270649
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Front Bioeng Biotechnol. 2021 Dec 01;9:785937
pubmed: 34926430
Br J Cancer. 1968 Jun;22(2):258-73
pubmed: 5660132
Lancet. 2013 Aug 24;382(9893):720-31
pubmed: 23972815
BMC Biol. 2012 Mar 22;10:29
pubmed: 22439642
Br J Cancer. 1985 Nov;52(5):739-46
pubmed: 4063148
Nature. 1987 May 21-27;327(6119):239-42
pubmed: 2952888
Biochem Biophys Res Commun. 2018 Dec 2;506(4):923-926
pubmed: 30392909
Exp Cell Res. 2010 May 1;316(8):1324-31
pubmed: 20211171
Int J Mol Sci. 2018 Oct 06;19(10):
pubmed: 30301213
Cell Death Dis. 2013 Nov 07;4:e915
pubmed: 24201814
Nat Biotechnol. 2022 Apr;40(4):555-565
pubmed: 34795433
Cancers (Basel). 2021 Sep 14;13(18):
pubmed: 34572836
Cancer Drug Resist. 2020 Oct 12;3(4):832-853
pubmed: 35582229
Science. 1988 Apr 8;240(4849):177-84
pubmed: 2451290
Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):206-9
pubmed: 8278366
Br J Cancer. 2014 Feb 4;110(3):724-32
pubmed: 24335925
Cancer Invest. 1990;8(6):655-7
pubmed: 2292060
Biotechniques. 2020 Nov;69(5):333-338
pubmed: 33000639
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
Biotechnol J. 2021 May;16(5):e2000463
pubmed: 33491924
Nat Genet. 2012 Jul 01;44(8):852-60
pubmed: 22751098
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Nat Med. 2011 Mar;17(3):320-9
pubmed: 21383745
N Engl J Med. 1971 Nov 18;285(21):1182-6
pubmed: 4938153
Drug Discov Today Technol. 2017 Mar;23:27-36
pubmed: 28647083
Mol Carcinog. 2013 Mar;52(3):167-82
pubmed: 22162252
PLoS One. 2014 Mar 24;9(3):e92511
pubmed: 24663399
J Cell Sci. 2010 Oct 15;123(Pt 20):3507-14
pubmed: 20841377
J Cell Biol. 2017 Nov 6;216(11):3509-3520
pubmed: 28931556
iScience. 2020 Oct 07;23(11):101649
pubmed: 33103086
Cell Regul. 1990 Dec;1(13):1003-14
pubmed: 2134746
Nat Rev Drug Discov. 2016 Nov;15(11):751-769
pubmed: 27616293
Clin Cancer Res. 2013 Jan 1;19(1):279-90
pubmed: 23091115
Oncotarget. 2017 Jun 28;8(44):76116-76128
pubmed: 29100297
Adv Cancer Res. 1974;19(0):331-58
pubmed: 4605404
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Medchemcomm. 2016 Oct 21;8(1):53-66
pubmed: 30108690
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352
pubmed: 32300252
Oncogene. 2010 Sep 23;29(38):5254-64
pubmed: 20603615
BMC Bioinformatics. 2016 Aug 24;17(1):317
pubmed: 27553370
Cancers (Basel). 2021 Jan 30;13(3):
pubmed: 33573362
Sci Rep. 2016 Nov 04;6:36641
pubmed: 27812005
EMBO Mol Med. 2014 Sep 11;6(10):1279-93
pubmed: 25214461
Cancer Lett. 2020 Nov 1;492:1-10
pubmed: 32712233
Front Cell Dev Biol. 2018 Apr 17;6:41
pubmed: 29719832
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Clin Cancer Res. 2009 Nov 1;15(21):6630-8
pubmed: 19843665
Br J Cancer. 1955 Dec;9(4):539-49
pubmed: 13304213
Drug Discov Today. 2013 Mar;18(5-6):240-9
pubmed: 23073387
J Cell Biol. 2012 Feb 20;196(4):395-406
pubmed: 22351925
J Biotechnol. 2010 Jul 1;148(1):3-15
pubmed: 20097238
Oncotarget. 2015 Apr 30;6(12):10146-60
pubmed: 25760142
Cancer Cells. 1991 Dec;3(12):525-9
pubmed: 1840291
Cancer Metab. 2019 Jun 01;7:6
pubmed: 31164982
Respir Investig. 2019 Jan;57(1):20-26
pubmed: 30293943
J Cell Biol. 1982 Oct;95(1):333-9
pubmed: 7142291